概述
-
货号
DHC34299
-
描述
Telisotuzumab vedotin is an ADC consisting of a cMET-directed antibody and Monomethyl auristatin E (MMAE) that has recently obtained the breakthrough therapy designation (BTD) for the treatment of patients with c-Met overexpression, advanced/metastatic wild-type (WT) epithelial growth factor receptor (EGFR) non-squamous non-small cell lung cancer (sqNSCLC) that progressed during or after platinum-based chemotherapy.
-
种属反应性
Human -
克隆类型
Monoclonal -
靶标
cMet -
浓度
1 mg/ml -
内毒素水平
Please contact with the lab for this information. -
纯度
>90% as determined by SEC. -
纯化方式
Purified by Ion Exchange Chromatography. -
克隆号
Telisotuzumab vedotin
-
应用
Research Grade Biosimilar -
状态
Liquid -
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. -
别名
ABBV-399
图片
参考文献
评价
